Literature DB >> 25941226

Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.

Peter M Keller1, Rico Hömke2, Claudia Ritter2, Giorgia Valsesia3, Guido V Bloemberg3, Erik C Böttger2.   

Abstract

Bedaquiline (Sirturo) and delamanid (Deltyba) have recently been approved by the regulatory authorities for treatment of multidrug-resistant tuberculosis (MDR-TB). Antimicrobial susceptibility testing is not established for either substance. On the basis of the use of the MGIT 960 system equipped with EpiCenter/TB eXiST, we determined a mean bedaquiline MIC for wild-type strains of 0.65 mg/liter (median, 0.4 mg/liter) and an epidemiological cutoff (ECOFF) of 1.6 mg/liter; for delamanid, a mean wild-type drug MIC of 0.013 mg/liter (median, 0.01 mg/liter) and an ECOFF of 0.04 mg/liter were determined.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25941226      PMCID： PMC4468675          DOI： 10.1128/AAC.00614-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  The ins and outs of Mycobacterium tuberculosis drug susceptibility testing.

Authors:  E C Böttger
Journal:  Clin Microbiol Infect       Date:  2011-06-01       Impact factor: 8.067

2.  Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824.

Authors:  Silke Feuerriegel; Claudio U Köser; Davide Baù; Sabine Rüsch-Gerdes; David K Summers; John A C Archer; Marc A Marti-Renom; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

Review 3.  Setting and revising antibacterial susceptibility breakpoints.

Authors:  John Turnidge; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

4.  A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.

Authors:  C K Stover; P Warrener; D R VanDevanter; D R Sherman; T M Arain; M H Langhorne; S W Anderson; J A Towell; Y Yuan; D N McMurray; B N Kreiswirth; C E Barry; W R Baker
Journal:  Nature       Date:  2000-06-22       Impact factor: 49.962

5.  Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.

Authors:  J Turnidge; G Kahlmeter; G Kronvall
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067

6.  Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients.

Authors:  A H Diacon; R Dawson; M Hanekom; K Narunsky; A Venter; N Hittel; L J Geiter; C D Wells; A J Paccaly; P R Donald
Journal:  Int J Tuberc Lung Dis       Date:  2011-07       Impact factor: 2.373

7.  Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.

Authors:  Marie-Claude Rouan; Nacer Lounis; Tom Gevers; Lieve Dillen; Ron Gilissen; Araz Raoof; Koen Andries
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

8.  A statistical approach for determination of disk diffusion-based cutoff values for systematic characterization of wild-type and non-wild-type bacterial populations in antimicrobial susceptibility testing.

Authors:  Giorgia Valsesia; Malgorzata Roos; Erik C Böttger; Michael Hombach
Journal:  J Clin Microbiol       Date:  2015-03-11       Impact factor: 5.948

9.  Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation.

Authors:  Burkhard Springer; Katja Lucke; Romana Calligaris-Maibach; Claudia Ritter; Erik C Böttger
Journal:  J Clin Microbiol       Date:  2009-04-01       Impact factor: 5.948

10.  OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.

Authors:  Makoto Matsumoto; Hiroyuki Hashizume; Tatsuo Tomishige; Masanori Kawasaki; Hidetsugu Tsubouchi; Hirofumi Sasaki; Yoshihiko Shimokawa; Makoto Komatsu
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069
View more
  14 in total

1.  A Multimethod, Multicountry Evaluation of Breakpoints for Bedaquiline Resistance Determination.

Authors:  Koné Kaniga; Shaheed V Omar; Nazir Ahmed Ismail; Akio Aono; Emanuele Borroni; Daniela Maria Cirillo; Christel Desmaretz; Rumina Hasan; Satoshi Mitarai; Sadia Shakoor; Gabriela Torrea
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

2.  Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis.

Authors:  Ji-Chan Jang; Yong-Gyun Jung; Jungil Choi; Hyunju Jung; Sungweon Ryoo
Journal:  J Microbiol       Date:  2017-04-20       Impact factor: 3.422

3.  Differential In Vitro Activities of Individual Drugs and Bedaquiline-Rifabutin Combinations against Actively Multiplying and Nutrient-Starved Mycobacterium abscessus.

Authors:  Jin Lee; Nicole Ammerman; Anusha Agarwal; Maram Naji; Si-Yang Li; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

4.  In Vitro Bedaquiline and Clofazimine Susceptibility Testing in Mycobacterium abscessus.

Authors:  Bettina Schulthess; Fatma Nur Akdoğan Kittana; Rico Hömke; Peter Sander
Journal:  Antimicrob Agents Chemother       Date:  2022-04-14       Impact factor: 5.938

5.  A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing.

Authors:  Koné Kaniga; Daniela M Cirillo; Sven Hoffner; Nazir A Ismail; Devinder Kaur; Nacer Lounis; Beverly Metchock; Gaby E Pfyffer; Amour Venter
Journal:  J Clin Microbiol       Date:  2016-09-21       Impact factor: 5.948

6.  Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study.

Authors:  R K R Rajoli; A T Podany; D M Moss; S Swindells; C Flexner; A Owen; M Siccardi
Journal:  Int J Tuberc Lung Dis       Date:  2018-08-01       Impact factor: 2.373

7.  Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress!

Authors:  Simon Tiberi; Andrea Maurizio Cabibbe; Jennifer Tomlins; Daniela Maria Cirillo; Giovanni Battista Migliori
Journal:  EBioMedicine       Date:  2018-02-08       Impact factor: 8.143

8.  Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.

Authors:  Jeong Seong Yang; Kyung Jong Kim; Hongjo Choi; Seung Heon Lee
Journal:  Ann Lab Med       Date:  2018-11       Impact factor: 3.464

9.  Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study.

Authors:  Nazir A Ismail; Shaheed V Omar; Lavania Joseph; Netricia Govender; Linsay Blows; Farzana Ismail; Hendrik Koornhof; Andries W Dreyer; Koné Kaniga; Norbert Ndjeka
Journal:  EBioMedicine       Date:  2018-01-09       Impact factor: 8.143

Review 10.  Whole Genome Sequencing for the Analysis of Drug Resistant Strains of Mycobacterium tuberculosis: A Systematic Review for Bedaquiline and Delamanid.

Authors:  Luisa Maria Nieto Ramirez; Karina Quintero Vargas; Gustavo Diaz
Journal:  Antibiotics (Basel)       Date:  2020-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.